PE-backed INC Research files for IPO

INC Research has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol “INCR.” Goldman Sachs and Credit Suisse are the lead underwriters. Based in Raleigh, NC, INC Research is global contract research organization for the biopharmaceutical and medical device industry. Its backers include Avista Capital Partners and the Ontario Teachers’ Pension Plan.

PRESS RELEASE

Raleigh, N.C., Oct. 6, 2014 – INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research and its stockholders and the price range for the offering have not yet been determined. The Company has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “INCR.” INC Research expects to use the net proceeds it receives from the offering to refinance its existing long-term debt as further specified in the registration statement.

Goldman, Sachs & Co. and Credit Suisse are serving as joint lead book-running managers for the offering. Baird, William Blair and Wells Fargo are serving as co-managers for the offering.

The offering will be made only by means of a prospectus. Once available, copies of the preliminary prospectus relating to the offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 866-471-2526, email: prospectus-ny@ny.email.gs.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: newyork.prospectus@credit-suisse.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification of such securities under the securities laws of any such state or jurisdiction.

About INC Research
INC Research is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked “Top CRO to Work With” by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries.